CTXR Share Price | Citius Pharmaceuticals, Inc. Stock Analysis & Recommendation

Q: How big is Citius Pharmaceuticals, Inc.?

Market Cap: As of Jun 18, Citius Pharmaceuticals, Inc. has a market capitalization of 9.54 million, classifying it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Citius Pharmaceuticals, Inc. reported net sales of 0.00 million and a consolidated net profit of -43.44 million.Balance Sheet Snapshot: As of Sep 24, the company reported shareholder's funds of 70.08 million and total assets of 116.65 million.

Q: What does Citius Pharmaceuticals, Inc. do?

Overview:Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing anti-infective products in adjunct cancer care, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot:Most recent Net Profit: -12 Million (Quarterly Results - Mar 2025) Market cap: USD 9.54 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: 0.00 Return on Equity: -71.62% Price to Book: 0.16 Contact Details:Address: 11 Commerce Dr Fl 1, CRANFORD NJ : 07016-3501 Tel: 1 908 9676677 Website: https://www.citiuspharma.com/

Q: Who are in the management team of Citius Pharmaceuticals, Inc.?

As of March 2022, the management team of Citius Pharmaceuticals, Inc. includes the following individuals:- Mr. Leonard Mazur, who serves as the Executive Chairman of the Board and Secretary.- Mr. Myron Holubiak, who is the President, Chief Executive Officer, and a Director.- The board also includes several Independent Directors: Mr. Suren Dutia, Dr. Eugene Holuka, Mr. William Kane, Mr. Howard Safir, and Ms. Carol Webb.In summary, the management team is led by Mr. Leonard Mazur and Mr. Myron Holubiak, with additional support from a group of independent directors.

Q: Is Citius Pharmaceuticals, Inc. technically bullish or bearish?

As of 6 August 2025, the technical trend for Citius Pharmaceuticals, Inc. has changed from sideways to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish, but the overall sentiment is tempered by bearish signals from the Bollinger Bands and daily moving averages. The RSI shows a bullish signal on the monthly timeframe but no signal on the weekly. The KST indicates a bullish stance weekly but is bearish monthly, and Dow Theory reflects a mildly bullish weekly outlook against a mildly bearish monthly view. In terms of performance, Citius Pharmaceuticals has significantly underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -70.75% versus the S&P's 12.22%, and a one-year return of -90.82% compared to the S&P's 17.14%. Overall, the current technical stance is mildly bearish, driven primarily by the bearish daily moving averages and Bollinger Bands, despite some mixed signals from other indicators.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

196.78 k

Shareholding (Sep 2025)

FII

0.40%

Held by 19 FIIs

DII

95.62%

Held by 4 DIIs

Promoter

0.00%

How big is Citius Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Citius Pharmaceuticals, Inc. has a market capitalization of 9.54 million, classifying it as a Micro Cap company, with total assets of 116.65 million and shareholder's funds of 70.08 million. The company reported net sales of 0.00 million and a consolidated net profit of -43.44 million for the latest four quarters.

View full answer

What does Citius Pharmaceuticals, Inc. do?

22-Jun-2025

Citius Pharmaceuticals, Inc. is a micro-cap specialty pharmaceutical company focused on developing anti-infective products for adjunct cancer care. As of March 2025, it reported a net profit loss of $12 million and has a market cap of $9.54 million.

View full answer

Who are in the management team of Citius Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, Citius Pharmaceuticals, Inc. is led by Executive Chairman Mr. Leonard Mazur and CEO Mr. Myron Holubiak, supported by independent directors including Mr. Suren Dutia, Dr. Eugene Holuka, Mr. William Kane, Mr. Howard Safir, and Ms. Carol Webb.

View full answer

Is Citius Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of August 6, 2025, Citius Pharmaceuticals, Inc. shows a mildly bearish trend overall, influenced by bearish daily moving averages and Bollinger Bands, despite some mixed bullish signals from the MACD and RSI, and has significantly underperformed the S&P 500 with a year-to-date return of -70.75%.

View full answer

Compare Citius Pharmaceuticals, Inc. with Similar Stocks

Cutera, Inc.Hyperfine, Inc.KORU Medical Systems, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 17 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.05

Return on Equity

-58.83%

Price to Book

0.25

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-9 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-43.28%

6 Months

-44.5%

1 Year

-70.22%

2 Years

-95.07%

3 Years

-43.28%

4 Years

-48.91%

5 Years

-97.66%

Citius Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-182.74%

EBIT to Interest (avg)

-33.14

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

Tax Ratio

1.92%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

9.22%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.14

EV to EBIT

-0.21

EV to EBITDA

-0.21

EV to Capital Employed

0.15

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-70.72%

ROE (Latest)

-71.62%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 14 Schemes (3.98%)

Foreign Institutions

Held by 19 Foreign Institutions (0.4%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 21.62% vs -12.12% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.40",
          "val2": "-11.00",
          "chgp": "23.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.70",
          "val2": "-11.10",
          "chgp": "21.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Sep 2025 is -0.76% vs -21.23% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-38.30",
          "val2": "-41.80",
          "chgp": "8.37%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-39.70",
          "val2": "-39.40",
          "chgp": "-0.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-8.40

-11.00

23.64%

Interest

0.10

0.00

Exceptional Items

0.00

Consolidate Net Profit

-8.70

-11.10

21.62%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 21.62% vs -12.12% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Sep'25

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-38.30

-41.80

8.37%

Interest

0.30

0.00

Exceptional Items

0.00

Consolidate Net Profit

-39.70

-39.40

-0.76%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in year ended Sep 2025 is -0.76% vs -21.23% in Sep 2024

All Annual Results

Company CV

About Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

Citius Pharmaceuticals Inc is a specialty pharmaceutical company. The Company is focused on developing and commercializing care products with a focus on anti-infective products in adjunct cancer care and prescription products. It has three product candidates: Mino-Lok, CITI-002 (halobetasol-lidocaine formulation) and CITI-101 (Mino-Wrap). Mino-Lok product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs). Mino-Lok product is designed to salvage the central venous catheters CVC, obviating the need to remove and replace the catheter. Mino-Wrap is a bio-absorbable film impregnated with minocycline and rifampin for reducing acute inflammation and microbial colonization of breast tissue expanders used in breast reconstruction surgeries following mastectomies. CITI-002 is being developed for symptomatic relief of hemorrhoids. CITI-002 combines the steroid, halobetasol, with lidocaine.

Company Coordinates

Company Details

11 Commerce Dr Fl 1 , CRANFORD NJ : 07016-3501

Tel: 1 908 9676677

https://www.citiuspharma.com/

Registrar Details

Citius Pharmaceuticals, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Citius Pharmaceuticals, Inc.?

Watch in Real-Time

What does Citius Pharmaceuticals, Inc. do?

Who are in the management team of Citius Pharmaceuticals, Inc.?

Is Citius Pharmaceuticals, Inc. technically bullish or bearish?

Compare Citius Pharmaceuticals, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Annual Results Snapshot (Consolidated) - Sep'25

About Citius Pharmaceuticals, Inc.

Company Coordinates